VCP and neoplasm: The study resulted in the identification of ML240 with improved potency towards inhibition of D2 ATPase activity.24 A derivative of ML240 was later developed into CB-5083, which displayed better specificity towards VCP and more importantly showed efficacy in several tumor xenograft models when administered orally.23,25 Such promising results allowed for the start of two Phase I clinical trials.